Preheparin serum lipoprotein lipase mass interacts with gender, gene polymorphism and, positively, with smoking

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 2, 2009, Pages 208-215

  Onat, Altan ^a,b,f   Hergenç, Gülay ^c   Agirbaşli, Mehmet ^d   Kaya, Zekeriya ^e   Can, Günay ^b   Ünaltuna, Nihan E ^b  

^a Turkish Society of Cardiology   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

^e Ko uyolu Kartal Heart Education and Research Hospital   (Turkey)

^f NONE   (Turkey)

Author keywords

Atherogenic dyslipidemia; Gender interaction; Lipoprotein lipase gene; Metabolic syndrome; Smoking habit

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; BODY MASS; CIGARETTE SMOKING; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TURKEY (REPUBLIC);

AGED; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPARIN; HUMANS; LINEAR MODELS; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SEX CHARACTERISTICS; SMOKING; TRIGLYCERIDES;

EID: 59949100464     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.018     Document Type: Conference Paper

References (30)

1. Kern PA, Martin RA, Carty J, Goldberg IJ, Ong JM. Identification of lipoprotein lipase immunoreactive protein in pre- and postheparin plasma from normal subjects and patients with type I hyperlipoproteinemia. J Lipid Res 1990;31:17-26.
2. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 2007;76:93-101.
3. Kobayashi J, Nohara A, Kawashiri MA, Inazu A, Koizumi J, Nakajima K, et al. Serum lipoprotein lipase mass: clinical significance of its measurement. Clin Chim Acta 2007;378:7-12.
4. Eckel RH, Goldberg IJ, Steiner L, Yost TJ, Paternity JR Jr. Plasma lipolytic activity and evidence for metabolic regulation. Diabetes 1988;37:610-5.
5. Hirano T, Nishioka F, Murakami T. Measurement of serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. Metabolism 2004;53:526-31.
6. Kobayashi J, Saito K, Fukamachi I, Taira K, Takahashi K, Bujo H, et al. Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res 2001;33:412-6.
7. Desmeules A, Bergeron J, Rankinen T, Bergeron J, Rankinen T, Leon AS, et al. Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: the HERITAGE Family Study. Atherosclerosis 2003;171:343-50.
8. Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 2004;174:385-90.
9. Henderson HE, Kastelein JJ, Zwinderman AH, Gagné E, Jukema JW, Reymer PW, et al. Lipoprotein lipase activity is decreased in a large cohort of patients with CAD and is associated with changes in lipids and lipoproteins. J Lipid Res 1999;40:735-43.
10. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, et al. Preheparin serum lipoprotein lipase is negatively related to coronary atherosclerosis. Atherosclerosis 2000;153:391-6.
11. Rip J, Nierman MC, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2006;26:637-42.
12. Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 1999;145:45-50.
13. Freeman DJ, Caslake MJ, Griffin BA, Hinnie J, Tan CE, Watson TD, et al. The effect of smoking on post-heparin lipoprotein lipase, cholesterol ester transfer protein and lecithin:cholesterol acyl-transferase activities in human plasma. Eur J Clin Invest 1998;28:584-91.
14. Kömürcü-Bayrak E, Onat A, Poda M, Humphries SE, Acharya J, Hergenc G, et al. The S447X variant of lipoprotein lipase gene is associated with metabolic syndrome and lipid levels among Turks. Clin Chim Acta 2007;383:110-5.
15. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-92.
16. Onat A, Avci GŞ, Şenocak M, Örnek E, Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidem Commun Health 1992;46:470-6.
17. Kobayashi J, Tashiro J, Murano S, Morisaki N, Saito Y. Lipoprotein lipase mass and activity in postheparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin Endocrinol 1998;48:515-20.
18. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) J Am Med Assoc 2001;285:2486-97.
19. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
20. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 2007;191:182-90.
21. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:3160-7.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentration in man. Diabetologia 1985;28:412-9.
23. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods, 2nd ed. Geneva: WHO, 1982:124-7.
24. Saito K, Sakurabayashi I, Manabe M. Serum lipoprotein lipase in healthy subjects: effects of gender and age, and relationships to lipid parameters. Ann Clin Biochem 1998;35:733-89.
25. Sorva R, Kuusi T, Taskinen MR. Effects of endogenous sex steroids on serum lipoproteins and post-heparin plasma lipolytic enzymes. J Clin Endocrinol Metab 1988;66:408-13.
26. Wung S-F, Kulkarni MV, Pullinger CR, Malloy MJ, Kane JP, Aouizerat BE. The lipoprotein lipase gene in combined hyperlipidemia: evidence of a protective allele depletion. Lipids Health Dis 2006;5:19.
27. Liu J, Zhao D, Liu J, Liu S, Qin LP, Wu ZS. The effect of lipoprotein lipase (LPL) polymorphism on plasma LPL concentration and triglyceride. Zhonghua Yi Xue Za Zhi 2005;85:1339-43 (in Chinese with English abstract).
28. Takefuji S, Yatsuya H, Tamakoshi K, Otsuka R, Wada K, Matsushita K, et al. Smoking status and adiponectin in healthy Japanese men and women. Prev Med 2007;45:471-5.
29. Onat A, Özhan H, Esen AM, Albayrak S, Karabulut A, Can G, et al. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women - without associated overall health benefit. Atherosclerosis 2007;193:380-9.
30. Nagaya T, Yoshida H, Takahashi H, Kawai M. Heavy smoking raises risk for type 2 diabetes mellitus in obese men, but light smoking reduces the risk in lean men: a follow-up study in Japan. Ann Epidemiol 2008;18:113-8.